OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod ...

Urcosimod has received FDA fast track designation for neuropathic corneal pain, enabling expedited regulatory processes and ...

The FDA granted fast track designation to urcosimod to treat neuropathic corneal pain, according to a press release from Okyo Pharma. Urcosimod, formerly called OK-101, is a “lipid conjugated chemerin ...

Urcosimod phase 2 trial treating Neuropathic Corneal Pain ("NCP”) patients was initiated in October 2024 and designed as a ...

US FDA grants fast track designation to OKYO Pharma’s urcosimod to treat neuropathic corneal pain: London Saturday, May 3, 2025, 17:00 Hrs [IST] OKYO Pharma Limited, an ophthalm ...

NCP is a debilitating condition characterized by severe pain and sensitivity of the eyes, face, or head, often due to nerve damage and inflammation of the cornea. Currently, there is no FDA ...

BNP Secretary General Mirza Fakhrul Islam Alamgir has said the problems with India are created by India itself by providing ...

DHAKA, April 23, 2025 (BSS) - BNP Standing Committee member Mirza Abbas today underscored the need for maintaining national ...

Family members of the victims of the July uprising, Pilkhana massacre, and Shapla Chattar massacre, along with leaders of various political parties, yesterday demanded a ban on the Awami League and ...